Pfizer Inc Stock Buy Hold or Sell Recommendation
| PFE Stock | USD 25.53 0.11 0.43% |
Considering the 90-day investment horizon and your complete indifference towards market risk, our recommendation regarding Pfizer Inc is 'Buy'. Macroaxis provides Pfizer buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Pfizer positions.
Check out Pfizer Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Pfizer and provide practical buy, sell, or hold advice based on investors' constraints. Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
Pfizer |
Execute Pfizer Buy or Sell Advice
The Pfizer recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Pfizer Inc. Macroaxis does not own or have any residual interests in Pfizer Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Pfizer's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Pfizer Trading Alerts and Improvement Suggestions
| Pfizer Inc has a poor financial position based on the latest SEC disclosures | |
| About 67.0% of the company shares are owned by institutional investors | |
| Latest headline from patch.com: Hoboken Parking And Street Cleaning Rules For Presidents Day Weekend |
Pfizer Returns Distribution Density
The distribution of Pfizer's historical returns is an attempt to chart the uncertainty of Pfizer's future price movements. The chart of the probability distribution of Pfizer daily returns describes the distribution of returns around its average expected value. We use Pfizer Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Pfizer returns is essential to provide solid investment advice for Pfizer.
| Mean Return | -0.03 | Value At Risk | -2.31 | Potential Upside | 2.20 | Standard Deviation | 1.52 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Pfizer historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Pfizer Stock Institutional Investors
| Shares | Northern Trust Corp | 2024-09-30 | 54.2 M | Capital World Investors | 2024-09-30 | 53.7 M | Amundi | 2024-09-30 | 47.1 M | Legal & General Group Plc | 2024-09-30 | 46.7 M | Bank Of New York Mellon Corp | 2024-12-31 | 39.9 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 38.1 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 33.4 M | Deutsche Bank Ag | 2024-09-30 | 32.4 M | Royal Bank Of Canada | 2024-09-30 | 31.9 M | Vanguard Group Inc | 2024-09-30 | 516.2 M | Blackrock Inc | 2024-09-30 | 436 M |
Pfizer Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (736M) | (1.1B) | 592M | 6.2B | 7.1B | 7.5B | |
| Change In Cash | 475M | 158M | (1.5B) | 2.4B | (2.9B) | (2.8B) | |
| Free Cash Flow | 11.6B | 29.9B | 26.0B | 4.8B | 5.5B | 10.5B | |
| Depreciation | 4.8B | 5.2B | 5.1B | 6.3B | 7.2B | 4.1B | |
| Other Non Cash Items | 3.6B | (4.8B) | 150M | 5.3B | (8.0B) | (7.6B) | |
| Dividends Paid | 8.4B | 8.7B | 9.0B | 9.2B | 10.6B | 11.2B | |
| Capital Expenditures | 2.6B | 2.8B | 2.7B | 3.2B | 3.9B | 0.0 | |
| Net Income | 7.0B | 22.5B | 31.4B | 2.2B | 8.0B | 9.3B | |
| End Period Cash Flow | 1.8B | 2.0B | 468M | 2.9B | 3.4B | 2.2B | |
| Change To Netincome | 2.9B | 2.9B | (7.3B) | (2.7B) | (2.5B) | (2.3B) | |
| Investments | (2.6B) | (19.5B) | 11.1B | (32.3B) | (37.1B) | (35.3B) | |
| Change Receivables | (742M) | (1.2B) | (3.8B) | 261M | 234.9M | 246.6M | |
| Net Borrowings | 8.8B | (12.8B) | (1.1B) | (3.5B) | (3.2B) | (3.0B) |
Pfizer Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Pfizer or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Pfizer's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Pfizer stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.04 | |
β | Beta against Dow Jones | 0.08 | |
σ | Overall volatility | 1.38 | |
Ir | Information ratio | -0.03 |
Pfizer Volatility Alert
Pfizer Inc exhibits very low volatility with skewness of 0.09 and kurtosis of 1.15. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pfizer's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pfizer's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Pfizer Fundamentals Vs Peers
Comparing Pfizer's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Pfizer's direct or indirect competition across all of the common fundamentals between Pfizer and the related equities. This way, we can detect undervalued stocks with similar characteristics as Pfizer or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Pfizer's fundamental indicators could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Pfizer to competition |
| Fundamentals | Pfizer | Peer Average |
| Return On Equity | 0.0885 | -0.31 |
| Return On Asset | 0.0331 | -0.14 |
| Profit Margin | 0.13 % | (1.27) % |
| Operating Margin | 0.16 % | (5.51) % |
| Current Valuation | 201.34 B | 16.62 B |
| Shares Outstanding | 5.67 B | 571.82 M |
| Shares Owned By Insiders | 0.20 % | 10.09 % |
| Shares Owned By Institutions | 67.41 % | 39.21 % |
| Number Of Shares Shorted | 73.57 M | 4.71 M |
| Price To Earning | 9.48 X | 28.72 X |
| Price To Book | 1.57 X | 9.51 X |
| Price To Sales | 2.27 X | 11.42 X |
| Revenue | 63.63 B | 9.43 B |
| Gross Profit | 47.21 B | 27.38 B |
| EBITDA | 11.11 B | 3.9 B |
| Net Income | 8.03 B | 570.98 M |
| Cash And Equivalents | 2.85 B | 2.7 B |
| Cash Per Share | 6.44 X | 5.01 X |
| Total Debt | (92.56 B) | 5.32 B |
| Debt To Equity | 0.40 % | 48.70 % |
| Current Ratio | 1.59 X | 2.16 X |
| Book Value Per Share | 16.29 X | 1.93 K |
| Cash Flow From Operations | 8.7 B | 971.22 M |
| Short Ratio | 2.07 X | 4.00 X |
| Earnings Per Share | 1.41 X | 3.12 X |
| Price To Earnings To Growth | 0.18 X | 4.89 X |
| Target Price | 31.18 | |
| Beta | 0.57 | -0.15 |
| Market Capitalization | 144.68 B | 19.03 B |
| Total Asset | 226.5 B | 29.47 B |
| Retained Earnings | 118.35 B | 9.33 B |
| Working Capital | (4.46 B) | 1.48 B |
| Current Asset | 43.8 B | 9.34 B |
Note: Disposition of 12038 shares by Boshoff Christoffel of Pfizer at 26.52 subject to Rule 16b-3 [view details]
Pfizer Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Pfizer . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Pfizer Buy or Sell Advice
When is the right time to buy or sell Pfizer Inc? Buying financial instruments such as Pfizer Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Pfizer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Pfizer Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Dividend Share 1.68 | Earnings Share 1.41 | Revenue Per Share | Quarterly Revenue Growth 0.247 |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.